ArticleJournal of oral microbiology2025
Hypochlorous acid solution serves as a potential anti-biofilm therapy for periodontitis
Article in Journal of oral microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oxidative Stress in Health and Disease: Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- Quorum sensing in oral multispecies biofilms: from interkingdom communication to therapeutic targeting.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgroud: Hypochlorous acid solution (HAS), a novel bio-friendly antimicrobial, has garnered attention for its antimicrobial activity, while less is known about its antibiofilm effects on periodontal pathogenic biofilms and the underlying mechanisms. Objective: This study aimed to explore HAS's antibiofilm effect on periodontal pathogenic biofilms and the potential mechanisms. Design: Results: Compared to 0.25% NaClO solution, it exhibited better biocompatibility. HAS downregulated biofilmvirulence factors and upregulated oxidative stress response-related genes, suggesting that inducing ROS production is a crucial mechanism of HAS in biofilm inhibition. Furthermore, HAS significantly inhibited autoinducer-2 (AI-2) activity and downregulated the QS-related genes. Conclusions: Given HAS's accessibility, excellent biocompatibility, and outstanding antibiofilm properties, it may offer a safe antibiofilm approach for clinical periodontal therapy, effectively removing biofilms in areas inaccessible to instrumental therapy and persistent biofilms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.